CCA
GMAB icon

Childress Capital Advisors’s Genmab GMAB Stock Holding History

Childress Capital Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-464
Closed -$19K – 476
2020
Q4 		$19K Buy
+464
New +$17.3K 0.01% 370

Other funds holding GMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Childress Capital Advisors's GMAB Position: Q1 2021 in Review

Childress Capital Advisors sold out of Genmab (GMAB) in Q1 2021, closing a stake of 464 shares — an estimated $19K sold.

Childress Capital Advisors first reported a position in GMAB in Q4 2020 and held it in 1 quarter. The position peaked at $19K in Q4 2020. 209 funds tracked by Wall St. Rank hold GMAB as of Q1 2021.

  • Childress Capital Advisors reported no remaining Genmab position as of Q1 2021 after selling out during the quarter.
  • Childress Capital Advisors sold 464 Genmab shares in Q1 2021, an estimated $19K.
  • Childress Capital Advisors first reported a position in Genmab in Q4 2020 and held it in 1 quarter.
  • Childress Capital Advisors's Genmab position peaked at $19K in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Genmab as of Q1 2021.

Based on Childress Capital Advisors's 13F filing for Q1 2021, filed 21 May 2021.